Vascular complications in diabetic patients with altered glycated hemoglobin admitted to Centro Médico Nacional - Hospital Nacional period 2022 – 2023
Article Sidebar
Main Article Content
Abstract
Introduction: diabetes mellitus is a chronic disease that, if not controlled, can lead to macro- and microvascular complications. One of the indicators of adequate glycemic control is glycosylated hemoglobin.
Objectives: to determine the frequency of macro and microvascular complications in type 2 diabetic patients with altered glycosylated hemoglobin admitted to the Hospital Nacional from 2022 to 2023.
Methodology: this was an observational, descriptive, cross-sectional study that included 170 adult patients admitted to the Internal Medicine service of the Hospital Nacional (Itauguá, Paraguay) during the years 2022 and 2023.
Results: the mean age was 58 ± 12 years, with a predominance of the female sex (51 %). The most frequently diagnosed complication was foot disease related to diabetes with 83 patients (49 %), followed by diabetic retinopathy 23 (14 %). The average value of glycosylated hemoglobin was 10 ± 2 %. Only 6 (4 %) of the total patients had an HbA1C value ≤7 %. The most frequent associated comorbidity was arterial hypertension 87 (51 %). 91 % of the patients knew they were carriers of the disease, 80 % received some type of treatment.
Conclusions: diabetic foot was the most frequently diagnosed vascular complication, especially in patients with HbA1C ≥7.1 %.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Liu C, Yang C, Zhao Y, Ma Z, Bi J, Liu Y, et al. Associations between long-term exposure to ambient particulate air pollution and type 2 diabetes prevalence, blood glucose and glycosylated hemoglobin levels in China. Environ Int. 2016;92–93:416–21. doi: 10.1016/j.envint.2016.03.028.
Dunn TC, Xu Y, Bergenstal RM, Ogawa W, Ajjan RA. Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator. Diabetes Technol Ther. 2023;25(S3):S65-S74. doi: 10.1089/dia.2023.0146
González N, Macías N, Loor M, Loor G. Sensibilidad y especificidad de la hemoglobina glicada para el control de diabetes mellitus tipo 2. Dom Cien 2021;7(5):248-260. doi: 10.23857/dc.v7i5.2246.
Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25-32. doi: 10.1177/2047487319878371.
Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2018;17(1):33. doi: 10.1186/s12933-018-0677-0.
Paraguay. Ministerio de Salud Pública y Bienestar Social. Boletín Suplemento Especial Diabetes. 2022. Asunción: El Ministerio. Disponible en: https://diabetes.mspbs.gov.py/boletinepidemiologico-2022/
Rangel ÉB, Rodrigues CO, de Sá JR. Micro- and macrovascular complications in diabetes mellitus: preclinical and clinical studies. J Diabetes Res. 2019; 2019:2161085. doi: 10.1155/2019/2161085.
Arnold SV, Khunti K, Tang F, Chen H, Nicolucci A, Gomes MB, et al. Impact of micro - and macrovascular complications of type 2 diabetes on quality of life: insights from the DISCOVER prospective cohort study. Endocrinol Diabetes Metab. 2022;5(2):e00321. doi: 10.1002/edm2.321.
Arnold SV, Khunti K, Tang F, Chen H, Cid-Ruzafa J, Cooper A, et al. Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: results from the longitudinal global discover study. Am Heart J. 2022;243:232-239. doi: 10.1016/j.ahj.2021.10.181.
Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150. doi: 10.1186/s12933-018-0787-8.
Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis †. Ann Med. 2017;49(2):106-116. doi: 10.1080/07853890.2016.1231932.
Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19(10):86. doi: 10.1007/s11892-019-1212-8.
Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(8):1808-1817. doi: 10.1161/ATVBAHA.120.314595.
Sidawy AN, Perler BA. Cirugía vascular y terapia endovascular de Rutherford. Filadelfia, PA: Elsevier; 2019.
Han D, Rozanski A, Gransar H, Sharir T, Einstein AJ, Fish MB, et al. Myocardial ischemic burden and differences in prognosis among patients with and without diabetes: results from the multicenter international REFINE SPECT registry. Diabetes Care. 2020;43(2):453-459. doi: 10.2337/dc19-1360.
Shah S, Abbas G, Aslam A, Randhawa FA, Khan FU, Khurram H, et al. Assessment of healthrelated quality of life among patients with obesity, hypertension and type 2 diabetes mellitus and its relationship with multimorbidity. PLoS One. 2023;18(8):e0289502. doi: 10.1371/journal.pone.0289502.
Fingeret M, Marques-Vidal P, Vollenweider P. Incidence of type 2 diabetes, hypertension, and dyslipidemia in metabolically healthy obese and non-obese. Nutr Metab Cardiovasc Dis. 2018;28(10):1036–1044. doi: 10.1016/j.numecd.2018.06.011.
Babu GR, Murthy G, Ana Y, Patel P, Deepa R, Neelon SE, et al. Association of obesity with hypertension and type 2 diabetes mellitus in India: a meta-analysis of observational studies. World J Diabetes. 2018;9(1):40-52. doi: 10.4239/wjd.v9.i1.40